A reality check for overdiagnosis estimates associated with breast cancer screening

Journal of the National Cancer Institute

Volumn 106, Issue 12, 2014, Pages

  Etzioni, Ruth ^a   Xia, Jing ^a   Hubbard, Rebecca ^b   Weiss, Noel S ^a,c   Gulati, Roman ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b GROUP HEALTH RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER SCREENING; CANCER SURVIVAL; CAUSE OF DEATH; HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; TUMOR INVASION; ADULT; ADVERSE EFFECTS; AGED; BREAST NEOPLASMS; EARLY DIAGNOSIS; FEMALE; INCIDENCE; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; PROCEDURES; RISK; STATISTICAL BIAS; TIME; UNITED STATES;

ADULT; AGED; BIAS (EPIDEMIOLOGY); BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; INCIDENCE; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; ODDS RATIO; TIME FACTORS; UNITED STATES;

EID: 84922394464     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju315     Document Type: Article

References (17)

1. Etzioni R, Gulati R, Mallinger L, et al. Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening. Ann Int Med. 2013;158(11):831-838.
2. Puliti D, Duffy SW, Miccinesi G, et al. Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen. 2012;19 Suppl 1:42-56.
3. Bleyer A, Welch HG. Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence. N Engl J Med. 2012;367(21):1998-2005.
4. Duffy SW, Chen HH, Tabar L, et al. Estimation of Mean Sojourn Time in Breast-Cancer Screening Using a Markov-Chain Model of Both Entry to and Exit from the Preclinical Detectable Phase. Stat Med. 1995;14(14):1531-1543.
5. Duffy SW, Chen HH, Tabar L, et al. Sojourn time, sensitivity and positive predictive value of mammography screening for breast cancer in women aged 40-49. Int J Epidemiol. 1996;25(6):1139-1145.
6. Shen Y, Zelen M. Screening Sensitivity and Sojourn Time From Breast Cancer Early Detection Clinical Trials: Mammograms and Physical Examinations. J Clin Oncol. 2001;19(15):3490-3499.
7. Walter SD, Day NE. Estimation of the duration of a pre-clinical disease state using screening data. Am J Epidemiol. 1983;118(6):865-886.
8. Chen JS, Prorok PC. Lead time estimation in a controlled screening program. Am J Epidemiol. 1983;118(5):740-751.
9. Etzioni R, Shen Y. Estimating asymptomatic duration in cancer: The AIDS connection. Stat Med. 1997;16(6):627-644.
10. Duffy SW, Parmar D. Overdiagnosis in breast cancer screening: the importance of length of observation period and lead time. Breast Cancer Res. 2013;15(3):R41.
11. Seiffert JE, Shambaugh EM, Kruse M, et al. SEER Program: Comparative Staging Guide for Cancer. Available at: http://seer. cancer.gov/archive/manuals/historic/comp-stage1.1.pdf.
12. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER∗Stat Database: Incidence - SEER 9 Regs Limited-Use, Nov 2012 Sub (1973-2010), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. Released April 2013, based on the November 2011 submission.
13. Weiss NS, Rossing MA. Healthy screenee bias in epidemiologic studies of cancer incidence. Epidemiol. 1996;7(3):319-322.
14. SEER∗Stat Software. Surveillance Research Program, National Cancer Institute SEER∗Stat software Version 8.1.5. Available at: http://seer. cancer.gov/seerstat/.
15. White E, Miglioretti DL, Yankaskas BC, et al. Biennial versus annual mammography and the risk of late-stage breast cancer. J Natl Cancer Inst. 2004;96(24):1832-1839.
16. Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014;348:g366
17. Etzioni R, Gulati R. RE: A model too far. J Natl Cancer Inst. 2014;106(4):dju058.